Why David Sans in New York Believes Axonal Transport Can Be Key to Helping People with Alzheimer's
NEW YORK, NY / ACCESSWIRE / October 1, 2021 / David Sans is a noted investor and a philanthropist in the healthcare industry. He looks at how axonal transport can be key to helping people function and survive in the face of diseases like Alzheimer's.
Alzheimer's isn't just a devastating disease, it's one that strips people of everything that makes them who they are. David Sans is a Chemical Engineer and an investor in cell therapy startups, and he's always on the watch for how new breakthroughs can be applied to benefit those who need it the most. He discusses how axonal transport works and how cell therapy could open possibilities for patients all over the world.
What Is Axonal Transport?
Axonal transport is the process of proteins steering and delivering any number of vital elements from one end of the nerve fiber to the other. When genes mutate, they can disrupt this activity, and this disruption seems to be the root cause of any number of neurological diseases.
David Sans is quick to point out that the research behind this is still in development, particularly when the theory is applied across the board. It's still unclear whether one is correlated or caused by the other. However, considering Alzheimer's causes neurons to die all over the brain and hampers the connections across brain regions, there could be something to concentrating on axonal transport as a potential solution for patients.
Cell Therapy for Axonal Transport
David Sans can tell you that brain atrophy doesn't just happen to people with Alzheimer's. From strokes to cancer, the impaired neurons affect all kinds of patients. So far, therapies involving stem cells have shown some degree of promise for axonal transport. David Sans has a Board Certification in Cell Therapies from Mt. Sinai. He also has more than a decade of investment banking experience in healthcare.
When Sans considers how different therapies match up to the needs of patients, he first examines the function the therapy is targeting. Axonal transport delivers some of the most important components of the body to the brain, including the organelles it needs to function. It seems clear that Alzheimer's patients would benefit greatly from a treatment that could simulate this vital process.
David Sans on Investment Principles
It's not a straightforward line in healthcare today, especially when the system has so many inherent flaws. Sans has to look at the disease, the methodology, and the promise behind each investment. Cell therapies have come a long way in the past few decades, but they're also up against any number of potential barriers. Improved axonal transport may offer hope to patients, but it needs to be properly developed and implemented first.
CONTACT:
Caroline Hunter
Web Presence, LLC
+1 7865519491
SOURCE: David Sans